Codexis (CDXS) Share-based Compensation (2010 - 2026)
Codexis (CDXS) posted quarterly Share-based Compensation of $1.4 million for Q1 2026, down 39.97% year-over-year from $2.4 million in Q1 2025, and up 119.23% quarter-over-quarter from -$7.4 million in Q4 2025.
Codexis (CDXS) Share-based Compensation (2010 - 2026) Analysis & Trends
Codexis' Share-based Compensation history runs 17 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 39.97% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at -$951000.0 (down 20.08% YoY), while the FY2023 annual figure was $10.0 million, down 31.38% from the prior year.
- Share-based Compensation for Q1 2026 stood at $1.4 million, up from -$7.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $13.0 million in Q4 2022, with the low at -$10.6 million in Q4 2024.
- The 5-year median for Share-based Compensation is $2.5 million (2025), against an average of $2.0 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation soared 328.33% in 2022, then sank 588.26% in 2024.
- Codexis' Share-based Compensation stood at $13.0 million in 2022, then tumbled by 83.42% to $2.2 million in 2023, then tumbled by 588.26% to -$10.6 million in 2024, then climbed by 29.7% to -$7.4 million in 2025, then surged by 119.23% to $1.4 million in 2026.
- Business Quant data shows CDXS's Share-based Compensation at $1.4 million in Q1 2026, -$7.4 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Codexis | 143.86 Mn | 88.95 Mn | 11.40 Mn | 1.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.58 Mn |
| Jun 30, 2026 | 1.58 Mn |
| Mar 31, 2026 | 1.43 Mn |
| Mar 31, 2026 | 1.43 Mn |
| Dec 31, 2025 | -7.42 Mn |
| Dec 31, 2025 | -7.42 Mn |
| Sep 30, 2025 | 2.51 Mn |
| Sep 30, 2025 | 2.51 Mn |
| Jun 30, 2025 | 2.53 Mn |
| Jun 30, 2025 | 2.53 Mn |
| Mar 31, 2025 | 2.38 Mn |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | -10.56 Mn |
| Dec 31, 2024 | -10.56 Mn |
| Sep 30, 2024 | 2.71 Mn |
| Sep 30, 2024 | 2.71 Mn |
| Jun 30, 2024 | 4.68 Mn |
| Jun 30, 2024 | 4.68 Mn |
| Mar 31, 2024 | 3.17 Mn |
| Mar 31, 2024 | 3.17 Mn |